SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY

Titia Q. Ruijs, Catherine M.K.E. de Cuba, Jules A.A.C. Heuberger, John Hutchison, Jane Bold, Thomas S. Grønnebæk, Klaus G Jensen, Eva Chin, Jorge A. Quiroz, Thomas K. Petersen, Peter Flagstad, Marieke L. de Kam, Michiel J. van Esdonk, Erica Klaassen, Robert J. Doll, Ingrid W. Koopmans, Annika A. de Goede, Thomas H. Pedersen, Geert Jan Groeneveld
doi: https://doi.org/10.1101/2024.02.15.24302858
Back to top
Posted February 17, 2024.
Download PDF

Supplementary Material

Data/Code
Email
SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY
Titia Q. Ruijs, Catherine M.K.E. de Cuba, Jules A.A.C. Heuberger, John Hutchison, Jane Bold, Thomas S. Grønnebæk, Klaus G Jensen, Eva Chin, Jorge A. Quiroz, Thomas K. Petersen, Peter Flagstad, Marieke L. de Kam, Michiel J. van Esdonk, Erica Klaassen, Robert J. Doll, Ingrid W. Koopmans, Annika A. de Goede, Thomas H. Pedersen, Geert Jan Groeneveld
medRxiv 2024.02.15.24302858; doi: https://doi.org/10.1101/2024.02.15.24302858
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area